About

About TFF

We are focused on developing innovative drug products based on our patented Thin Film Freezing, or TFF, technology platform.

Although intended for the lungs, many drugs are not given via the airway because drug properties make it too difficult to formulate for direct to lung delivery.

Administered systemically, these drugs often produce unwanted and potentially life-threatening side effects. To get around this, companies have tried to use microcapsules, carriers, and other agents to try to dose drugs direct to the lungs, but these other delivery agents often produce their own problems.

Using its proprietary technology, TFF can generate dry powder inhaler versions of many drugs using nothing but the drug itself and approved lung-friendly ingredients. This means that many drugs of all types – small molecules, biologics, even combinations – can be dosed direct to the lungs with fewer side effects.

Management

Glenn Mattes

President, Chief Executive Officer and Director

Glenn Mattes joined the company in May 2018, bringing more than 30 years of business leadership, global therapeutics development expertise, and executive management experience to his role with the company.

In his capacity as Chief Executive Officer, Mr. Mattes, has oversight of the direction and strategy at TFF Pharmaceuticals, facilitating company activity in business development, marketing, investor relations, commercialization alliances and channels, and management support. He works to share the company’s vision and strategy with partners, investors and shareholders.

As Executive Chairman of Translational Sciences, Inc. the company consummated a global strategic collaboration in 2015 with Daiichi Sankyo for its lead cardiovascular asset. Prior to joining Translational Sciences, Mr. Mattes was CEO of Arno Therapeutics, a publicly traded company with a portfolio of development stage oncology therapeutic compounds, and a highly regarded group of founding investors.

From 2002 thru 2011 Mr. Mattes served as President of Tibotec Therapeutics, a Johnson & Johnson operating company, where he led, from inception, the organization responsible for the development, marketing, sales and business development of oncology and novel antiretroviral therapeutics. Tibotec’s revenues grew from zero to approximately $1 billion under Mr. Mattes’ leadership. During his Tibotec tenure, he led the successful launch of the first two Johnson & Johnson products launched into the HIV/AIDS market and presided over the growth of both Doxil and Procrit in the oncology therapeutic and supportive care categories.

From 1998 thru 2002 Mr. Mattes served as Vice President of Worldwide Commercial and Clinical Operations at Centocor Inc. He played a critical role in defining the company’s overall business direction as well as developing and implementing the strategy leading to the growth of ReoPro and the commercial launch of Remicade.

Prior to joining Centocor Mr. Mattes was at Rhône Poulenc Rorer, where he held positions of increasing responsibility, including President of RPR Canada and General Manager of U.S. pharmaceuticals. At Rhône Poulenc Rorer he built a market-leading asthma and allergy business with a focus on inhalation therapies. In addition, he was the General Manager of Advanced Therapeutics and Oncology, North America, and headed the successful launches of two blockbuster drugs, Taxotere and Lovenox.

In 2008 Mr. Mattes was honored with an appointment to the President’s Advisory Council on HIV/AIDS by President George W. Bush and the U.S. Secretary of Health and Human Services. In his service to the United States as a member of PACHA he was a key contributor to the committee responsible for counseling both the Bush and Obama administrations on domestic and global health and treatment issues.

Mr. Mattes serves on the Boards of Advantagene, Inc., Deck Therapeutics, Cornovus, Inc. and CannaMetrix. He is an advisor to the Gores Group and Clayton Foundation for Research, and served as an advisor to PTV Healthcare Capital. He is also an Operating Partner of Revival Healthcare.

Mr. Mattes received a Bachelor of Science degree from the City University of New York.

Board of Directors

Glenn Mattes

President, Chief Executive Officer and Director

Mr. Mattes received a Bachelor of Science degree from the City University of New York.

Robert S. Mills

Executive Chairman of the Board

Mr. Mills is a 39-year veteran in the pharmaceutical industry. Bob’s expertise ranges across GMP Operations, Clinical Research, Regulatory Affairs and Commercial Operations as well as R&D, IT, Product Development, Technical Services, Manufacturing, Engineering and Quality Assurance. Mr. Mills has a large network of industry relationships, as well as a very strong track record successfully managing businesses, delivering quality products, successfully interacting with the FDA, and generating attractive growth through expanding market share and launching exciting new products.

Most recently, he was the President and CEO of Scientific Protein Labs (SPL), the US’s leading manufacturer of heparin and pancreatin. Recently, Mr. Mills sold SPL to a Chinese pharmaceutical company for 3 times the original purchase price and with milestone payments over the next several years could be as high as 5 times the original purchase price.

Prior to SPL, Mr. Mills was President of Qualitest Pharmaceuticals, a leading manufacturer and distributor of generic pharmaceuticals. He joined Qualitest in early 2010 with the specific charge to grow the business at a quicker pace. In less than one year, monthly net sales increased by over 50 percent. In late 2010, Qualitest was acquired by Endo Pharmaceuticals for $1.2 billion or 15 times EBITDA.

Prior to Qualitest, Mr. Mills was recruited to Columbia Laboratories, Inc. in 2001 to solve a worldwide recall issue for the principal product and re-launched the product to the marketing partner within 4 months. He was also responsible for a product with a completely new delivery system being approved on its PDUFA date and after becoming CEO in 2006 more than doubled sales to $36 million in two years. As Vice President and General Manager of Watson/Schein’s solid dose division, after correcting a number of quality and regulatory issues through a voluntary corrective action plan with FDA, the Company received 5 new product approvals. The launch of these products coupled with operational efficiencies resulted in an improvement of profitability in one year by $60 million which was instrumental in Schein being acquired by Watson.

Mr. Mills served as Vice President of Operations at Alpharma, Inc. from 1993 to 1996. Prior to Alpharma, Mr. Mills held various positions with Sanofi including Director-Plant Operations, Rhone-Poulenc Rorer. His business development experience has led to multiple product acquisitions, joint ventures and product divestitures. He was recognized as a finalist for Entrepreneur of the Year for New Jersey in 2009 by Ernst and Young. Mr. Mills holds a B.S. Degree from Grove City College and numerous graduate business credits from Temple University.

Collaboration Opportunities

We continue to work with the inventors of the TFF platform through a series of Sponsored Research Agreements, or SRAs, with UT. Pursuant to those agreements, the research scientists, together with their labs and collaborators, provide expertise and initial development work, including:

the preliminary development and in vitro evaluation of our drug candidates;
the determination of the key characteristics influencing performance of our product candidates;
the determination of the formulation and manufacturing parameters that influence the key characteristics of our product candidates;
supply of bulk dry powders for initial good laboratory practice, or GLP, and non-GLP toxicity studies;
supportive stability for future GLP and GMP studies; and
the evaluation of the in vivo performance of our product candidates in various animal models.

Pathway to Market

Because our dry powder drug candidates will represent a new formulation of an existing drug, we will need to obtain FDA approval of the TFF prepared drug candidate before we can begin commercialization. However, because we begin our formulation with a drug that has previously received FDA approval in another form, we believe that in most cases we should qualify for the FDA’s 505(b)(2) regulatory pathway, which potentially will take less time and investment than the standard FDA approval process.

About TFF

Management

Glenn Mattes

Brian Windsor, Ph.D.

Kirk Coleman

Board of Directors

Glenn Mattes

Brian Windsor, Ph.D.

Aaron Fletcher, Ph.D.

Robert S. Mills

Stephen Rocamboli

Harlan Weisman, M.D.

Randy Thurman

Malcolm Fairbairn

Collaboration Opportunities

Pathway to Market